The estimated Net Worth of Richard M. Wright is at least $3.38 million dollars as of 3 June 2024. Richard Wright owns over 67,469 units of Celldex Therapeutics stock worth over $2,818,070 and over the last 8 years he sold CLDX stock worth over $0. In addition, he makes $563,171 as Senior Vice President et Chief Commercial Officer at Celldex Therapeutics.
Sign up
Richard Wright CLDX stock SEC Form 4 insiders trading
Richard has made over 3 trades of the Celldex Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 67,469 units of CLDX stock worth $1,267,743 on 3 June 2024.
The largest trade he's ever made was exercising 67,469 units of Celldex Therapeutics stock on 3 June 2024 worth over $1,267,743. On average, Richard trades about 8,636 units every 106 days since 2016. As of 3 June 2024 he still owns at least 67,677 units of Celldex Therapeutics stock.
You can see the complete history of Richard Wright stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard Wright biography
Dr. Richard Wright Ph.D. serves as Senior Vice President, Chief Commercial Officer of the Company. Dr. Wright served as Vice President of Commercial Operations of Celldex from April 2012 to July 2015. From November 2010 to April 2012, Dr. Wright was Managing Director of Navigant Consulting, a global life sciences consulting practice. From September 2003 to October 2010, Dr. Wright held several senior leadership roles at Bristol-Myers Squibb including Senior Vice President of the U.S. ImmunoScience Division. Dr. Wright currently serves on the Scientific Advisory Board for the Seaver Foundation, a nonprofit organization supporting the Center for Autism Treatment and Research at Mount Sinai Hospital. Dr. Wright received his B.S. in Biological Sciences from Rutgers University and his M.S. and Ph.D. in Microbiology and Molecular Genetics from The University of Medicine and Dentistry of New Jersey (Rutgers University). He received an M.B.A. in Marketing and Finance from Columbia University.
What is the salary of Richard Wright?
As the Senior Vice President et Chief Commercial Officer of Celldex Therapeutics, the total compensation of Richard Wright at Celldex Therapeutics is $563,171. There are 8 executives at Celldex Therapeutics getting paid more, with Ronald Pepin having the highest compensation of $1,225,030.
How old is Richard Wright?
Richard Wright is 56, he's been the Senior Vice President et Chief Commercial Officer of Celldex Therapeutics since 2015. There are 17 older and 7 younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics Inc. is Herbert Conrad, 87, who is the Independent Director.
What's Richard Wright's mailing address?
Richard's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.
Insiders trading at Celldex Therapeutics
Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil et Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.
What does Celldex Therapeutics do?
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
What does Celldex Therapeutics's logo look like?
Complete history of Richard Wright stock trades at Celldex Therapeutics
Celldex Therapeutics executives and stock owners
Celldex Therapeutics executives and other stock owners filed with the SEC include:
-
Ronald Pepin,
Senior Vice President and Chief Business Officer -
Anthony Marucci,
President, Chief Executive Officer, Director -
Anthony S. Marucci M.B.A.,
Founder, Pres, CEO & Director -
Tibor Keler,
Executive Vice President and Chief Scientific Officer -
Dr. Tibor Keler,
Founder, Chief Scientific Officer & Exec. VP -
Dr. Diane C. Young M.D.,
Sr. VP & Chief Medical Officer -
Margo Heath-Chiozzi,
Senior Vice President - Regulatory Affairs -
Sam Martin,
Chief Financial Officer, Senior Vice President, Secretary -
Richard Wright,
Senior Vice President, Chief Commercial Officer -
Dr. Margo Heath-Chiozzi M.D.,
Sr. VP of Regulatory Affairs -
Elizabeth Crowley,
Senior Vice President, Chief Product Development Officer -
Sam Martin,
Sr. VP, CFO, Sec. & Treasurer -
Elizabeth Crowley,
Chief Product Devel. Officer & Sr. VP -
Karen Shoos,
Independent Chairman of the Board -
Keith Brownlie,
Independent Director -
James Marino,
Independent Director -
Harry Penner,
Independent Director -
Herbert Conrad,
Independent Director -
Diane Young,
Senior Vice President, Chief Medical Officer -
Sarah Cavanaugh,
Senior Vice President - Corporate Affairs and Administration -
Prof. Joseph P. Schlessinger Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Dr. Richard M. Wright Ph.D.,
Chief Commercial Officer & Sr. VP -
Dr. Ronald A. Pepin,
Chief Bus. Officer & Sr. VP -
Freddy A. Jimenez Esq.,
Sr. VP & Gen. Counsel -
Patrick Till,
Sr. Director of Investor Relations & Corp. Communications -
Sarah Cavanaugh,
Sr. VP of Corp. Affairs & Admin. -
Theresa La Vallee,
SVP, Reg.& Precision Medicine -
Larry Ellberger,
Director -
George Elston,
Director -
Gerald Ph D Mc Mahon,
Director -
Avery W Catlin,
Sr. VP & CFO -
Den Broek Richard Van,
Director -
Rita Jain,
-
Timothy M Shannon,
Director -
Rajesh B Parekh,
Director -
Charles R Schaller,
Director -
Inc Medarex,
10% owner -
Ronald C Newbold,
Sr. VP, Business Dev. -
Cheryl Cohen,
-
Freddy A. Jimenez,
SVP & GENERAL COUNSEL -
Garry Arthur Neil,